The purpose of this clinical study was to evaluate whether vaginal tablets containing 10 mg dequalinium chloride (Fluomizin) are comparable in clinical efficacy and safety to clindamycin vaginal cream (2%) in patients suffering from bacterial vaginosis.

An international, multi-center, single-blind, randomized, active-controlled study with two parallel groups in patients with bacterial vaginosis. Eligible patients were randomized to receive Fluomizin vaginal tablets for 6 days or Clindamycin vaginal cream (2%) for 7 days. Control examinations were performed 3 to 14 days and 2 to 6 weeks after the end of the therapy.

Inclusion Criteria:

• Diagnosis of bacterial vaginosis
• Women aged 18-55 years

Exclusion Criteria:

• Pregnancy or lactation
• Uterine bleeding (including menstruation but not including cervical contact bleeding on sampling) or vaginal bleeding of unknown origin
• Acute infections of the upper genital tract
• Clinical Symptoms of a vulvovaginal Candidiasis
• Use of anti-infectives (local or systemic) in the previous 14 days and/or during the study